Literature DB >> 26347074

The immunogenetics of Behçet's disease: A comprehensive review.

Masaki Takeuchi1, Daniel L Kastner2, Elaine F Remmers3.   

Abstract

Behçet's disease is a chronic multisystem inflammatory disorder characterized mainly by recurrent oral ulcers, ocular involvement, genital ulcers, and skin lesions, presenting with remissions and exacerbations. It is thought that both environmental and genetic factors contribute to its onset and development. Although the etiology of Behçet's disease remains unclear, recent immunogenetic findings are providing clues to its pathogenesis. In addition to the positive association of HLA-B*51, which was identified more than four decades ago, and which has since been confirmed in multiple populations, recent studies report additional independent associations in the major histocompatibility complex class I region. HLA-B*15, -B*27, -B*57, and -A*26 are independent risk factors for Behçet's disease, while HLA-B*49 and -A*03 are independent class I alleles that are protective for Behçet's disease. Genome-wide association studies have identified associations with genome-wide significance (P < 5 × 10(-8)) in the IL23R-IL12RB2, IL10, STAT4, CCR1-CCR3, KLRC4, ERAP1, TNFAIP3, and FUT2 loci. In addition, targeted next-generation sequencing has revealed the involvement of rare nonsynonymous variants of IL23R, TLR4, NOD2, and MEFV in Behçet's disease pathogenesis. Significant differences in gene function or mRNA expression associated with the risk alleles of the disease susceptibility loci suggest which genes in a disease-associated locus influence disease pathogenesis. These genes encompass both innate and adaptive immunity and confirm the importance of the predominant polarization towards helper T cell (Th) 1 versus Th2 cells, and the involvement of Th17 cells. In addition, epistasis observed between HLA-B*51 and the risk coding haplotype of the endoplasmic reticulum-associated protease, ERAP1, provides a clue that an HLA class I-peptide presentation-based mechanism contributes to this complex disease. Published by Elsevier Ltd.

Entities:  

Keywords:  Behçet's disease; Disease-associated genetic variants; ERAP1; GWAS; HLA-B*51

Mesh:

Year:  2015        PMID: 26347074      PMCID: PMC4628864          DOI: 10.1016/j.jaut.2015.08.013

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  134 in total

1.  Evidence for linkage of the HLA-B locus in Behçet's disease, obtained using the transmission disequilibrium test.

Authors:  A Gül; A H Hajeer; J Worthington; J H Barrett; W E Ollier; A J Silman
Journal:  Arthritis Rheum       Date:  2001-01

Review 2.  Current concepts in the etiology and treatment of Behçet disease.

Authors:  Cem Evereklioglu
Journal:  Surv Ophthalmol       Date:  2005 Jul-Aug       Impact factor: 6.048

3.  EULAR recommendations for the management of Behçet disease.

Authors:  G Hatemi; A Silman; D Bang; B Bodaghi; A M Chamberlain; A Gul; M H Houman; I Kötter; I Olivieri; C Salvarani; P P Sfikakis; A Siva; M R Stanford; N Stübiger; S Yurdakul; H Yazici
Journal:  Ann Rheum Dis       Date:  2008-01-31       Impact factor: 19.103

4.  Genome-wide association study identifies GIMAP as a novel susceptibility locus for Behcet's disease.

Authors:  Yun Jong Lee; Yukihiro Horie; Graham R Wallace; Yong Seok Choi; Ji Ah Park; Ji Yong Choi; Ran Song; Young-Mo Kang; Seong Wook Kang; Han Joo Baek; Nobuyoshi Kitaichi; Akira Meguro; Nobuhisa Mizuki; Kenichi Namba; Susumu Ishida; Jinhyun Kim; Edyta Niemczyk; Eun Young Lee; Yeong Wook Song; Shigeaki Ohno; Eun Bong Lee
Journal:  Ann Rheum Dis       Date:  2012-10-06       Impact factor: 19.103

5.  Behçet disease-associated MHC class I residues implicate antigen binding and regulation of cell-mediated cytotoxicity.

Authors:  Michael J Ombrello; Yohei Kirino; Paul I W de Bakker; Ahmet Gül; Daniel L Kastner; Elaine F Remmers
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-12       Impact factor: 11.205

6.  The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9.

Authors:  V Braud; E Y Jones; A McMichael
Journal:  Eur J Immunol       Date:  1997-05       Impact factor: 5.532

7.  The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses.

Authors:  David L Boone; Emre E Turer; Eric G Lee; Regina-Celeste Ahmad; Matthew T Wheeler; Colleen Tsui; Paula Hurley; Marcia Chien; Sophia Chai; Osamu Hitotsumatsu; Elizabeth McNally; Cecile Pickart; Averil Ma
Journal:  Nat Immunol       Date:  2004-08-29       Impact factor: 25.606

8.  Brief report: high-throughput sequencing of IL23R reveals a low-frequency, nonsynonymous single-nucleotide polymorphism that is associated with ankylosing spondylitis in a Han Chinese population.

Authors:  Stuart I Davidson; Lei Jiang; Adrian Cortes; Xin Wu; Evgeny A Glazov; Marina Donskoi; Yi Zheng; Patrick A Danoy; Yi Liu; Gethin P Thomas; Matthew A Brown; Huji Xu
Journal:  Arthritis Rheum       Date:  2013-07

9.  Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection.

Authors:  Stephen E Girardin; Ivo G Boneca; Jérôme Viala; Mathias Chamaillard; Agnès Labigne; Gilles Thomas; Dana J Philpott; Philippe J Sansonetti
Journal:  J Biol Chem       Date:  2003-01-13       Impact factor: 5.157

10.  Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47.

Authors:  Carl A Anderson; Gabrielle Boucher; Charlie W Lees; Andre Franke; Mauro D'Amato; Kent D Taylor; James C Lee; Philippe Goyette; Marcin Imielinski; Anna Latiano; Caroline Lagacé; Regan Scott; Leila Amininejad; Suzannah Bumpstead; Leonard Baidoo; Robert N Baldassano; Murray Barclay; Theodore M Bayless; Stephan Brand; Carsten Büning; Jean-Frédéric Colombel; Lee A Denson; Martine De Vos; Marla Dubinsky; Cathryn Edwards; David Ellinghaus; Rudolf S N Fehrmann; James A B Floyd; Timothy Florin; Denis Franchimont; Lude Franke; Michel Georges; Jürgen Glas; Nicole L Glazer; Stephen L Guthery; Talin Haritunians; Nicholas K Hayward; Jean-Pierre Hugot; Gilles Jobin; Debby Laukens; Ian Lawrance; Marc Lémann; Arie Levine; Cecile Libioulle; Edouard Louis; Dermot P McGovern; Monica Milla; Grant W Montgomery; Katherine I Morley; Craig Mowat; Aylwin Ng; William Newman; Roel A Ophoff; Laura Papi; Orazio Palmieri; Laurent Peyrin-Biroulet; Julián Panés; Anne Phillips; Natalie J Prescott; Deborah D Proctor; Rebecca Roberts; Richard Russell; Paul Rutgeerts; Jeremy Sanderson; Miquel Sans; Philip Schumm; Frank Seibold; Yashoda Sharma; Lisa A Simms; Mark Seielstad; A Hillary Steinhart; Stephan R Targan; Leonard H van den Berg; Morten Vatn; Hein Verspaget; Thomas Walters; Cisca Wijmenga; David C Wilson; Harm-Jan Westra; Ramnik J Xavier; Zhen Z Zhao; Cyriel Y Ponsioen; Vibeke Andersen; Leif Torkvist; Maria Gazouli; Nicholas P Anagnou; Tom H Karlsen; Limas Kupcinskas; Jurgita Sventoraityte; John C Mansfield; Subra Kugathasan; Mark S Silverberg; Jonas Halfvarson; Jerome I Rotter; Christopher G Mathew; Anne M Griffiths; Richard Gearry; Tariq Ahmad; Steven R Brant; Mathias Chamaillard; Jack Satsangi; Judy H Cho; Stefan Schreiber; Mark J Daly; Jeffrey C Barrett; Miles Parkes; Vito Annese; Hakon Hakonarson; Graham Radford-Smith; Richard H Duerr; Séverine Vermeire; Rinse K Weersma; John D Rioux
Journal:  Nat Genet       Date:  2011-02-06       Impact factor: 38.330

View more
  61 in total

1.  Peripheral blood mononuclear cell proteome profile in Behçet's syndrome.

Authors:  Asli Kirectepe Aydin; Yeşim Özgüler; Didar Uçar; Murat Kasap; Gürler Akpınar; Emire Seyahi; Eda Tahir Turanli
Journal:  Rheumatol Int       Date:  2019-08-14       Impact factor: 2.631

Review 2.  An update on the role of epigenetics in systemic vasculitis.

Authors:  Patrick Coit; Haner Direskeneli; Amr H Sawalha
Journal:  Curr Opin Rheumatol       Date:  2018-01       Impact factor: 5.006

3.  Intracardiac thrombosis in Behçet's Disease successfully treated with immunosuppressive agents: A case of vascular pathergy phenomenon.

Authors:  Francisco Galeano-Valle; Pablo Demelo-Rodriguez; Luís Álvarez-Sala-Walther; Blanca Pinilla-Llorente; Miguel Jesús Echenagusia-Boyra; Hugo Rodriguez-Abella; Jorge Del-Toro-Cervera
Journal:  Intractable Rare Dis Res       Date:  2018-02

4.  Lack of association between polymorphisms in interleukin (IL)-12, IL-12R, IL-23, IL-23R genes and Takayasu arteritis in a Chinese population.

Authors:  Kun-Qi Yang; Yan-Kun Yang; Xu Meng; Ying Zhang; Xiong-Jing Jiang; Hai-Ying Wu; Hui-Min Zhang; Lei Song; Jin Bian; Dan Wen; Lin-Ping Wang; Xian-Liang Zhou
Journal:  Inflamm Res       Date:  2016-03-17       Impact factor: 4.575

Review 5.  The Immune Response and the Pathogenesis of Idiopathic Inflammatory Myositis: a Critical Review.

Authors:  Angela Ceribelli; Maria De Santis; Natasa Isailovic; M Eric Gershwin; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

6.  [Clinical analysis of golimumab in the treatment of severe/refractory cardiovascular involvement in Behcet syndrome].

Authors:  L X Sun; J J Liu; Y X Hou; C R Li; L Li; X P Tian; X F Zeng; W J Zheng
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2020-12-18

Review 7.  Autoimmunity in 2016.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

Review 8.  Is Behçet's disease a 'class 1-opathy'? The role of HLA-B*51 in the pathogenesis of Behçet's disease.

Authors:  M Giza; D Koftori; L Chen; P Bowness
Journal:  Clin Exp Immunol       Date:  2017-10-06       Impact factor: 4.330

Review 9.  Autoimmunity in 2015.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2016-08       Impact factor: 8.667

10.  Behçet's Disease: Pulmonary Aneurysm Resolution with Oral Therapy and HLA B72 Allele Association.

Authors:  Clarissa de Albuquerque Botura; Luiz Eduardo Bersani-Amado; Antônio Rubens Zacarias-Júnior; Sueli Donizete Boreli; Naiene Gomes Gordo Stecca; Bruno Ambrósio da Rocha; Roberto Kenji Nakamura Cuman; Ciomar Aparecida Bersani-Amado
Journal:  Clin Med Res       Date:  2018-04-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.